You are here

bosutinib

Bosutinib

Treatment type:

Code name: 
SKI-606
Commercial name: 
Bosulif
Treatment line: 
  • Second line
  • Third line
  • Fourth line
  • Fifth line
Generation: 
Second

Bosutinib (Bosulif, Pfizer) is a second generation tyrosine kinase inhibitor that inhibits Abl‑kinases including Bcr‑Abl kinase. It also inhibits the Src family kinases, which have been implicated in driving chronic myeloid leukaemia (CML) progression. Bosutinib is administered orally. The recommended dose is 500 mg once daily. A dose escalation of up to 600 mg is permitted if a complete haematological response has not occurred by week 8 or a complete cytogenetic response by week 12. Bosutinib is indicated for the treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options. 

Status: 
England
Available as a routine treatment for its licensed indications
Scotland
Available as a routine treatment for its licensed indications
Wales
Available as a routine treatment for its licensed indications
Northern Ireland
Available as a routine treatment for its licensed indications
type: Clinical trial
published: 15 November 2015
categories:
type: Event
published: 6 November 2015
categories:
type: Clinical trial
published: 28 June 2015
categories:
type: Video
published: 19 May 2015
categories:
type: Article
published: 6 May 2015
categories: